Cooled radiofrequency ablation for the treatment of refractory postamputation neuroma‐associated pain: A prospective pilot study
PM&R · 2026
DOI: 10.1002/pmrj.13412 ↗Kurz gefasst
Fachartikel in der Zeitschrift PM&R, 2026. Verfasst von Cole W Cheney und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pain Medicine, Mayo Clinic Health Systems, Mankato, Minnesota, USA. Hauptthemen laut MEDLINE: Radiofrequency Ablation, Amputation, Surgical, Postoperative Pain, Neuroma. Die Arbeit nennt 40 Literaturangaben. Gefördert von: Foundation for Physical Medicine and Rehabilitation.
Abstract (Originalsprache)
Background
Radiofrequency ablation (RFA) of neuromas has emerged as a potential treatment option for refractory neuroma‐associated postamputation pain (PAP).
Objective
To evaluate the feasibility of using internally cooled radiofrequency ablation (C‐RFA) for treating neuroma‐associated PAP.
Design
Prospective single‐arm pilot study.
Setting
Tertiary academic medical center.
Participants
Eight participants with neuroma‐associated PAP (mean age 56.5 [ interquartile range, 50.5–68.5] years; mean body mass index 30.2 [ interquartile range, 26.3–34.8] kg/m 2 ).
Intervention
Participants were recruited and treated with C‐RFA between 2019 and 2023. Main Outcome Measures Pain and functional outcomes were assessed at 1, 3, 6, and 12 months after C‐RFA using Numeric Rating Scale (NRS), Groningen Activity Restriction Scale (GARS), Patient Global Impression of Change (PGIC), and Medication Quantification Scale III (MQS‐III). Responder definitions for each outcome measure were ≥50% NRS reduction, ≥30% GARS improvement, ≥6 on PGIC, and ≥6.8‐point MQS‐III reduction.
Results
NRS responder rates at 1, 3, 6, and 12 months were 25.0% (95% CI, 7.0%–59.1%), 50.0% (95% CI, 21.5%–78.5%), 37.5% (95% CI, 13.7%–69.4%), and 50.0% (95% CI, 21.5%–78.5%), respectively. Responder rates for GARS were 25.0% (95% CI, 7.1%–59.1%) at 1 month and 12.5% (95% CI, 2.2%–47.1%) at 3, 6, and 12 months. The proportion of PGIC responders was 37.5% (95% CI, 13.7%–69.4%) at 1 and 3 months and 12.5% (95% CI, 2.2%–47.1%) at 6 and 12 months. MQS‐III responder rates were 25.0% (95% CI, 7.1%–59.1%) at 1 month, 12.5% (95% CI, 2.2%–47.1%) at 3 months, and 37.5% (95% CI, 13.7%–69.4%) at 6 and 12 months. There were no complications associated with the C‐RFA procedure.
Conclusions
These findings indicate the feasibility of neuroma C‐RFA as a treatment for refractory neuroma‐associated PAP but also suggest that further patient selection and C‐RFA technique optimization are warranted before investigating this treatment paradigm in a larger prospective study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Division of Pain Medicine, Mayo Clinic Health Systems, Mankato, Minnesota, USA.
- Department of Anesthesiology, McGaw Medical Center of Northwestern University, Chicago, Illinois, USA.
- Department of Physical Medicine and Rehabilitation, University of Utah, Salt Lake City, Utah, USA.
- Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
ORCID-Profile: Cole W Cheney, Colby Hansen, Amanda N Cooper, Zachary L McCormick
Förderung
- Foundation for Physical Medicine and Rehabilitation
Zitieren
APA
Cheney, C. W., Mele, K., Kendall, R., Hansen, C., Sperry, B. P., Cooper, A. N., Burnham, T., Conger, A., & McCormick, Z. L. (2026). Cooled radiofrequency ablation for the treatment of refractory postamputation neuroma‐associated pain: A prospective pilot study. PM&R. https://doi.org/10.1002/pmrj.13412
Vancouver
Cheney CW, Mele K, Kendall R, Hansen C, Sperry BP, Cooper AN, et al. Cooled radiofrequency ablation for the treatment of refractory postamputation neuroma‐associated pain: A prospective pilot study. PM&R. 2026. doi:10.1002/pmrj.13412
BibTeX
@article{Cheney2026,
author = {Cheney, Cole W and Mele, Kyle and Kendall, Richard and Hansen, Colby and Sperry, Beau P and Cooper, Amanda N and Burnham, Taylor and Conger, Aaron and McCormick, Zachary L},
title = {Cooled radiofrequency ablation for the treatment of refractory postamputation neuroma‐associated pain: A prospective pilot study},
journal = {PM&R},
year = {2026},
doi = {10.1002/pmrj.13412}
}
EUVIMED